Clinical Trial Update: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update notes the termination of a Phase 2 study evaluating copanlisib in combination with rituximab-bendamustine for relapsed-refractory dif…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• Rituximab (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED